Major Neurologic Adverse Drug Reactions, Potential Drug-Drug Interactions and Pharmacokinetic Aspects of Drugs Used in COVID-19 Patients with Stroke: A Narrative Review.
Identifieur interne : 001134 ( Main/Corpus ); précédent : 001133; suivant : 001135Major Neurologic Adverse Drug Reactions, Potential Drug-Drug Interactions and Pharmacokinetic Aspects of Drugs Used in COVID-19 Patients with Stroke: A Narrative Review.
Auteurs : Parisa Ghasemiyeh ; Afshin Borhani-Haghighi ; Iman Karimzadeh ; Soliman Mohammadi-Samani ; Afsaneh Vazin ; Anahid Safari ; Adnan I. QureshiSource :
- Therapeutics and clinical risk management [ 1176-6336 ] ; 2020.
Abstract
Stroke has been considered as one of the underlying diseases that increases the probability of severe infection and mortality. Meanwhile, there are ongoing reports of stroke subsequent to COVID-19 infection. In this narrative paper, we reviewed major neurologic adverse drug reactions (ADRs) and pharmacokinetics of drugs which are routinely used for COVID-19 infection and their potential drug-drug interactions (PDDIs) with common drugs used for the treatment of stroke. It is highly recommended to monitor patients on chloroquine (CQ), hydroxychloroquine (HCQ), antiviral drugs, and/or corticosteroids about initiation or progression of cardiac arrhythmias, delirium, seizure, myopathy, and/or neuropathy. In addition, PDDIs of anti-COVID-19 drugs with tissue plasminogen activator (tPA), anticoagulants, antiaggregants, statins, antihypertensive agents, and iodine-contrast agents should be considered. The most dangerous PDDIs were interaction of lopinavir/ritonavir or atazanavir with clopidogrel, prasugrel, and new oral anticoagulants (NOACs).
DOI: 10.2147/TCRM.S259152
PubMed: 32669846
PubMed Central: PMC7335700
Links to Exploration step
pubmed:32669846Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Major Neurologic Adverse Drug Reactions, Potential Drug-Drug Interactions and Pharmacokinetic Aspects of Drugs Used in COVID-19 Patients with Stroke: A Narrative Review.</title><author><name sortKey="Ghasemiyeh, Parisa" sort="Ghasemiyeh, Parisa" uniqKey="Ghasemiyeh P" first="Parisa" last="Ghasemiyeh">Parisa Ghasemiyeh</name><affiliation><nlm:affiliation>Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Pharmaceutical Sciences Research Center, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Borhani Haghighi, Afshin" sort="Borhani Haghighi, Afshin" uniqKey="Borhani Haghighi A" first="Afshin" last="Borhani-Haghighi">Afshin Borhani-Haghighi</name><affiliation><nlm:affiliation>Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Karimzadeh, Iman" sort="Karimzadeh, Iman" uniqKey="Karimzadeh I" first="Iman" last="Karimzadeh">Iman Karimzadeh</name><affiliation><nlm:affiliation>Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Mohammadi Samani, Soliman" sort="Mohammadi Samani, Soliman" uniqKey="Mohammadi Samani S" first="Soliman" last="Mohammadi-Samani">Soliman Mohammadi-Samani</name><affiliation><nlm:affiliation>Pharmaceutical Sciences Research Center, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Pharmaceutics, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Vazin, Afsaneh" sort="Vazin, Afsaneh" uniqKey="Vazin A" first="Afsaneh" last="Vazin">Afsaneh Vazin</name><affiliation><nlm:affiliation>Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Safari, Anahid" sort="Safari, Anahid" uniqKey="Safari A" first="Anahid" last="Safari">Anahid Safari</name><affiliation><nlm:affiliation>Stem Cells Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Qureshi, Adnan I" sort="Qureshi, Adnan I" uniqKey="Qureshi A" first="Adnan I" last="Qureshi">Adnan I. Qureshi</name><affiliation><nlm:affiliation>Zeenat Qureshi Stroke Institute and Department of Neurology, University of Missouri, Columbia, MO, USA.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32669846</idno><idno type="pmid">32669846</idno><idno type="doi">10.2147/TCRM.S259152</idno><idno type="pmc">PMC7335700</idno><idno type="wicri:Area/Main/Corpus">001134</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001134</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Major Neurologic Adverse Drug Reactions, Potential Drug-Drug Interactions and Pharmacokinetic Aspects of Drugs Used in COVID-19 Patients with Stroke: A Narrative Review.</title><author><name sortKey="Ghasemiyeh, Parisa" sort="Ghasemiyeh, Parisa" uniqKey="Ghasemiyeh P" first="Parisa" last="Ghasemiyeh">Parisa Ghasemiyeh</name><affiliation><nlm:affiliation>Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Pharmaceutical Sciences Research Center, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Borhani Haghighi, Afshin" sort="Borhani Haghighi, Afshin" uniqKey="Borhani Haghighi A" first="Afshin" last="Borhani-Haghighi">Afshin Borhani-Haghighi</name><affiliation><nlm:affiliation>Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Karimzadeh, Iman" sort="Karimzadeh, Iman" uniqKey="Karimzadeh I" first="Iman" last="Karimzadeh">Iman Karimzadeh</name><affiliation><nlm:affiliation>Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Mohammadi Samani, Soliman" sort="Mohammadi Samani, Soliman" uniqKey="Mohammadi Samani S" first="Soliman" last="Mohammadi-Samani">Soliman Mohammadi-Samani</name><affiliation><nlm:affiliation>Pharmaceutical Sciences Research Center, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Pharmaceutics, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Vazin, Afsaneh" sort="Vazin, Afsaneh" uniqKey="Vazin A" first="Afsaneh" last="Vazin">Afsaneh Vazin</name><affiliation><nlm:affiliation>Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Safari, Anahid" sort="Safari, Anahid" uniqKey="Safari A" first="Anahid" last="Safari">Anahid Safari</name><affiliation><nlm:affiliation>Stem Cells Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Qureshi, Adnan I" sort="Qureshi, Adnan I" uniqKey="Qureshi A" first="Adnan I" last="Qureshi">Adnan I. Qureshi</name><affiliation><nlm:affiliation>Zeenat Qureshi Stroke Institute and Department of Neurology, University of Missouri, Columbia, MO, USA.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Therapeutics and clinical risk management</title><idno type="ISSN">1176-6336</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Stroke has been considered as one of the underlying diseases that increases the probability of severe infection and mortality. Meanwhile, there are ongoing reports of stroke subsequent to COVID-19 infection. In this narrative paper, we reviewed major neurologic adverse drug reactions (ADRs) and pharmacokinetics of drugs which are routinely used for COVID-19 infection and their potential drug-drug interactions (PDDIs) with common drugs used for the treatment of stroke. It is highly recommended to monitor patients on chloroquine (CQ), hydroxychloroquine (HCQ), antiviral drugs, and/or corticosteroids about initiation or progression of cardiac arrhythmias, delirium, seizure, myopathy, and/or neuropathy. In addition, PDDIs of anti-COVID-19 drugs with tissue plasminogen activator (tPA), anticoagulants, antiaggregants, statins, antihypertensive agents, and iodine-contrast agents should be considered. The most dangerous PDDIs were interaction of lopinavir/ritonavir or atazanavir with clopidogrel, prasugrel, and new oral anticoagulants (NOACs).</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32669846</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1176-6336</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>Therapeutics and clinical risk management</Title><ISOAbbreviation>Ther Clin Risk Manag</ISOAbbreviation></Journal><ArticleTitle>Major Neurologic Adverse Drug Reactions, Potential Drug-Drug Interactions and Pharmacokinetic Aspects of Drugs Used in COVID-19 Patients with Stroke: A Narrative Review.</ArticleTitle><Pagination><MedlinePgn>595-605</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/TCRM.S259152</ELocationID><Abstract><AbstractText>Stroke has been considered as one of the underlying diseases that increases the probability of severe infection and mortality. Meanwhile, there are ongoing reports of stroke subsequent to COVID-19 infection. In this narrative paper, we reviewed major neurologic adverse drug reactions (ADRs) and pharmacokinetics of drugs which are routinely used for COVID-19 infection and their potential drug-drug interactions (PDDIs) with common drugs used for the treatment of stroke. It is highly recommended to monitor patients on chloroquine (CQ), hydroxychloroquine (HCQ), antiviral drugs, and/or corticosteroids about initiation or progression of cardiac arrhythmias, delirium, seizure, myopathy, and/or neuropathy. In addition, PDDIs of anti-COVID-19 drugs with tissue plasminogen activator (tPA), anticoagulants, antiaggregants, statins, antihypertensive agents, and iodine-contrast agents should be considered. The most dangerous PDDIs were interaction of lopinavir/ritonavir or atazanavir with clopidogrel, prasugrel, and new oral anticoagulants (NOACs).</AbstractText><CopyrightInformation>© 2020 Ghasemiyeh et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ghasemiyeh</LastName><ForeName>Parisa</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-8640-5724</Identifier><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmaceutical Sciences Research Center, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borhani-Haghighi</LastName><ForeName>Afshin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karimzadeh</LastName><ForeName>Iman</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohammadi-Samani</LastName><ForeName>Soliman</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-1007-1422</Identifier><AffiliationInfo><Affiliation>Pharmaceutical Sciences Research Center, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmaceutics, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vazin</LastName><ForeName>Afsaneh</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2230-4449</Identifier><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Safari</LastName><ForeName>Anahid</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8272-291X</Identifier><AffiliationInfo><Affiliation>Stem Cells Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qureshi</LastName><ForeName>Adnan I</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>Zeenat Qureshi Stroke Institute and Department of Neurology, University of Missouri, Columbia, MO, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Ther Clin Risk Manag</MedlineTA><NlmUniqueID>101253281</NlmUniqueID><ISSNLinking>1176-6336</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">adverse drug reactions</Keyword><Keyword MajorTopicYN="N">pharmacokinetics</Keyword><Keyword MajorTopicYN="N">potential drug–drug interactions</Keyword><Keyword MajorTopicYN="N">stroke</Keyword></KeywordList><CoiStatement>The authors have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>06</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32669846</ArticleId><ArticleId IdType="doi">10.2147/TCRM.S259152</ArticleId><ArticleId IdType="pii">259152</ArticleId><ArticleId IdType="pmc">PMC7335700</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nature. 2020 Mar;579(7798):270-273</Citation><ArticleIdList><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 May 7;382(19):1787-1799</Citation><ArticleIdList><ArticleId IdType="pubmed">32187464</ArticleId></ArticleIdList></Reference><Reference><Citation>Medicine (Baltimore). 2017 Aug;96(34):e7474</Citation><ArticleIdList><ArticleId IdType="pubmed">28834869</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Discov Ther. 2020;14(1):58-60</Citation><ArticleIdList><ArticleId IdType="pubmed">32147628</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Allergy Asthma Immunol. 1999 Dec;83(6 Pt 1):495-503; quiz 503-4</Citation><ArticleIdList><ArticleId IdType="pubmed">10619339</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Cardiol. 2020 Mar 27;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32219363</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Sci. 2014 Mar 15;338(1-2):96-101</Citation><ArticleIdList><ArticleId IdType="pubmed">24380687</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2002 Feb;59(2):195-201</Citation><ArticleIdList><ArticleId IdType="pubmed">11843689</ArticleId></ArticleIdList></Reference><Reference><Citation>Iran J Med Sci. 2014 Nov;39(6):515-21</Citation><ArticleIdList><ArticleId IdType="pubmed">25429173</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayo Clin Proc. 2020 Jun;95(6):1213-1221</Citation><ArticleIdList><ArticleId IdType="pubmed">32359771</ArticleId></ArticleIdList></Reference><Reference><Citation>Regul Toxicol Pharmacol. 2009 Feb;53(1):46-51</Citation><ArticleIdList><ArticleId IdType="pubmed">19010373</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacol Ther. 2020 Aug;108(2):242-247</Citation><ArticleIdList><ArticleId IdType="pubmed">32246834</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2020 May;177:104762</Citation><ArticleIdList><ArticleId IdType="pubmed">32147496</ArticleId></ArticleIdList></Reference><Reference><Citation>J Palliat Med. 2017 Mar;20(3):298-299</Citation><ArticleIdList><ArticleId IdType="pubmed">27875666</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Respir Med. 2020 May;8(5):e32-e33</Citation><ArticleIdList><ArticleId IdType="pubmed">32222169</ArticleId></ArticleIdList></Reference><Reference><Citation>Daru. 2014 Jan 22;22(1):20</Citation><ArticleIdList><ArticleId IdType="pubmed">24450358</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1964 Jun 1;188:779-84</Citation><ArticleIdList><ArticleId IdType="pubmed">14132530</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacokinet. 2005;44(10):1035-50</Citation><ArticleIdList><ArticleId IdType="pubmed">16176117</ArticleId></ArticleIdList></Reference><Reference><Citation>Sultan Qaboos Univ Med J. 2013 Aug;13(3):E476-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23984041</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Rev Oncol Hematol. 2020 Jul;151:102982</Citation><ArticleIdList><ArticleId IdType="pubmed">32460133</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2003 Jan 10;959(2):280-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12493616</ArticleId></ArticleIdList></Reference><Reference><Citation>Muscle Nerve. 2008 Sep;38(3):1206-10</Citation><ArticleIdList><ArticleId IdType="pubmed">18720511</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Ophthalmol. 1994 Mar 15;117(3):352-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8129010</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Mar;55(3):105924</Citation><ArticleIdList><ArticleId IdType="pubmed">32081636</ArticleId></ArticleIdList></Reference><Reference><Citation>J Thromb Haemost. 2020 Apr;18(4):844-847</Citation><ArticleIdList><ArticleId IdType="pubmed">32073213</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharm Res. 2004 Sep;21(9):1622-30</Citation><ArticleIdList><ArticleId IdType="pubmed">15497688</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroke. 2012 Jun;43(6):1711-37</Citation><ArticleIdList><ArticleId IdType="pubmed">22556195</ArticleId></ArticleIdList></Reference><Reference><Citation>Radiology. 2020 Jun;295(3):200463</Citation><ArticleIdList><ArticleId IdType="pubmed">32077789</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidney Int. 2020 May;97(5):829-838</Citation><ArticleIdList><ArticleId IdType="pubmed">32247631</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2018 Jun;28(5):354-359</Citation><ArticleIdList><ArticleId IdType="pubmed">29638141</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurohospitalist. 2017 Jan;7(1):41-48</Citation><ArticleIdList><ArticleId IdType="pubmed">28042370</ArticleId></ArticleIdList></Reference><Reference><Citation>Q J Med. 1971 Jan;40(157):85-93</Citation><ArticleIdList><ArticleId IdType="pubmed">4253656</ArticleId></ArticleIdList></Reference><Reference><Citation>Seizure. 1992 Sep;1(3):183-5</Citation><ArticleIdList><ArticleId IdType="pubmed">1344765</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2014 May;13(5):525-34</Citation><ArticleIdList><ArticleId IdType="pubmed">24685278</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Med. 2020 Feb 20;9(2):</Citation><ArticleIdList><ArticleId IdType="pubmed">32093211</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1981 Apr;38(4):471-7</Citation><ArticleIdList><ArticleId IdType="pubmed">7212976</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Metab Syndr. 2020 May - Jun;14(3):247-250</Citation><ArticleIdList><ArticleId IdType="pubmed">32247212</ArticleId></ArticleIdList></Reference><Reference><Citation>Scand J Rheumatol. 1976;5(3):161-66</Citation><ArticleIdList><ArticleId IdType="pubmed">981992</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Feb 7;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1996 Oct 5;348(9032):917-21</Citation><ArticleIdList><ArticleId IdType="pubmed">8843810</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2015 Oct 10;386(10002):1465-71</Citation><ArticleIdList><ArticleId IdType="pubmed">26466051</ArticleId></ArticleIdList></Reference><Reference><Citation>J Postgrad Med. 2000 Jan-Mar;46(1):29-30</Citation><ArticleIdList><ArticleId IdType="pubmed">10855075</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2020 Jun;178:104787</Citation><ArticleIdList><ArticleId IdType="pubmed">32251768</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Pediatr. 2020 Jun;16(3):271-274</Citation><ArticleIdList><ArticleId IdType="pubmed">32166483</ArticleId></ArticleIdList></Reference><Reference><Citation>Gen Hosp Psychiatry. 2014 Mar-Apr;36(2):181-6</Citation><ArticleIdList><ArticleId IdType="pubmed">24290896</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1991 Mar;41(3):437-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1848688</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2016 May 18;6:26173</Citation><ArticleIdList><ArticleId IdType="pubmed">27188341</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2002 Jun;4(3):171-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12003678</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Hypotheses. 2020 Apr 27;142:109783</Citation><ArticleIdList><ArticleId IdType="pubmed">32402766</ArticleId></ArticleIdList></Reference><Reference><Citation>Molecules. 2020 Mar 30;25(7):</Citation><ArticleIdList><ArticleId IdType="pubmed">32235534</ArticleId></ArticleIdList></Reference><Reference><Citation>Mil Med Res. 2020 Feb 6;7(1):4</Citation><ArticleIdList><ArticleId IdType="pubmed">32029004</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1983 Nov;140(11):1426-36</Citation><ArticleIdList><ArticleId IdType="pubmed">6624987</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Apr;55(4):105944</Citation><ArticleIdList><ArticleId IdType="pubmed">32179150</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroke Vasc Neurol. 2020 Jun;5(2):146-151</Citation><ArticleIdList><ArticleId IdType="pubmed">32385132</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Neuropharmacol. 2011 Mar-Apr;34(2):79-83</Citation><ArticleIdList><ArticleId IdType="pubmed">21412202</ArticleId></ArticleIdList></Reference><Reference><Citation>Graefes Arch Clin Exp Ophthalmol. 2013 Jan;251(1):255-60</Citation><ArticleIdList><ArticleId IdType="pubmed">22441810</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Stroke. 2007 Nov;2(4):270-5</Citation><ArticleIdList><ArticleId IdType="pubmed">18705927</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Respir J. 2020 May 14;55(5):</Citation><ArticleIdList><ArticleId IdType="pubmed">32217650</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Med. 2020 Apr;14(2):185-192</Citation><ArticleIdList><ArticleId IdType="pubmed">32170560</ArticleId></ArticleIdList></Reference><Reference><Citation>J Can Assoc Gastroenterol. 2018 Sep;1(3):99-106</Citation><ArticleIdList><ArticleId IdType="pubmed">31294728</ArticleId></ArticleIdList></Reference><Reference><Citation>Case Rep Neurol Med. 2014;2014:428425</Citation><ArticleIdList><ArticleId IdType="pubmed">25309765</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Respir Med. 2020 Apr;8(4):e21</Citation><ArticleIdList><ArticleId IdType="pubmed">32171062</ArticleId></ArticleIdList></Reference><Reference><Citation>Rheumatol Int. 2004 Sep;24(5):315-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14740170</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Nephrol. 2018 Oct 22;19(1):283</Citation><ArticleIdList><ArticleId IdType="pubmed">30348107</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Apr 23;382(17):e38</Citation><ArticleIdList><ArticleId IdType="pubmed">32268022</ArticleId></ArticleIdList></Reference><Reference><Citation>Otolaryngol Head Neck Surg. 1996 Mar;114(3):491-3</Citation><ArticleIdList><ArticleId IdType="pubmed">8649890</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacokinet. 2000 Sep;39(3):167-83</Citation><ArticleIdList><ArticleId IdType="pubmed">11020133</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Apr;55(4):105933</Citation><ArticleIdList><ArticleId IdType="pubmed">32147516</ArticleId></ArticleIdList></Reference><Reference><Citation>Heart. 1999 Feb;81(2):221-3</Citation><ArticleIdList><ArticleId IdType="pubmed">9922366</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropathology. 2018 Dec;38(6):646-652</Citation><ArticleIdList><ArticleId IdType="pubmed">30411412</ArticleId></ArticleIdList></Reference><Reference><Citation>Postepy Dermatol Alergol. 2018 Aug;35(4):429-430</Citation><ArticleIdList><ArticleId IdType="pubmed">30206460</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001134 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001134 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32669846
|texte= Major Neurologic Adverse Drug Reactions, Potential Drug-Drug Interactions and Pharmacokinetic Aspects of Drugs Used in COVID-19 Patients with Stroke: A Narrative Review.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32669846" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |